FCER2 and Alzheimer disease: In our previous study with the same group of patients we confirmed in AD patients treated with dupilumab the higher count of CD16+ eosinophils (activated eosinophils) and the higher association between the count of eosinophils (absolute and relative) and the expression of CD23 marker on B cells.